Antibacterial composition, application and medicine
Through the combination of trans cinnamaldehyde and multiple antibiotics, the antibiotic sensitivity of drug-resistant bacteria is reversed, the treatment problem of multi-drug-resistant bacteria is solved, the amount of antibiotics is significantly reduced, and food safety is ensured.
Patent Information
- Application Number
- CN202411080202.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-07
- Publication Date
- 2024-11-15
- Estimated Expiration
- 2044-08-07
AI Technical Summary
The long-term abuse of antibacterial drugs has caused resistance to antibacterial drugs by Bacillus pleuropneumoniae, Streptococcus suis and Staphylococcus suis, increasing the difficulty of treatment and drug residues, threatening food safety and public health.
The combination of trans cinnamaldehyde and antibiotics such as amoxicillin, penicillin G, ciprofloxacin, erythromycin, lincomycin and other antibiotics is prepared through different proportions to reverse the antibiotic sensitivity of drug-resistant bacteria. Significantly reduce the amount of antibiotics used and prepare drugs that are made into oral fluids, injections, tablets or granules.
This composition has a good inhibitory or killing effect on multidrug-resistant bacteria, significantly reduces the amount of antibiotics used, avoids antibiotic residues in pork food, and ensures food safety.
Smart Images

Figure CN118949047A_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of antibiotics, and more specifically, relates to an antibacterial composition, application and medicine. Background Art
[0002] Exudative epidermitis in piglets is mainly caused by Staphylococcus hyicus, which is a systemic exudative inflammation of the skin. The lesions are characterized by the release of oily exudates, and may also cause bacteremia, sepsis and arthritis in piglets. Piglets eventually lose fluid through the skin and become dehydrated, leading to death. After recovery, they show growth retardation. The incidence rate varies greatly, up to 80%. Staphylococcus hyicus has been found in the skin, nasal mucosa, conjunctiva, genitals (sow vagina, boar foreskin) and breeding environment of asymptomatic carrier pigs. When the environmental conditions are humid and warm, they are often prone to large-scale reproduction, or when the piglet's immune system is low, it will cause the onset and transmission of exudative dermatitis in piglets. This disease has become one of the common and frequent infectious diseases in the current pig farming process that affects the growth of piglets.
[0003] Up to 20% of porcine bacterial pneumonia cases are caused by Actinobacillus pleuropneumoniae. Actinobacillus pleuropneumoniae is a Gram-negative, non-motile, naturally transformable, facultative anaerobic bacterium with coccobacillus morphology. Clinical symptoms caused by its infection include dyspnea in sows, frothy blood in oral secretions, fever, anorexia, mild diarrhea, cyanosis, lethargy and abortion. Pigs that do not die from the disease still carry highly virulent porcine bacterial pneumonia after recovery. There have been many reports of A. pleuropneumoniae developing resistance to antibiotics such as aminoglycosides, β-lactams, fluoroquinolones, macrolides, sulfonamides, and tetracyclines. This pathogen is also a common pathogen in pig farming and has a profound economic impact on pork production and pig farmers.
[0004] Streptococcus suis, caused by infection with Streptococcus suis, is considered the main infectious disease in the pig industry, with clinical features of meningitis, sepsis or arthritis. It causes significant economic losses to the pig industry worldwide every year. S. suis is prevalent in almost all countries with large-scale pig farming. It is also a zoonosis that can be transmitted to humans through pigs. Infection with S. suis may cause severe meningitis, sepsis, endocarditis and deafness. The use of antibiotics for treatment and prevention is very common in the pig farming industry, making S. suis increasingly resistant to drugs and becoming an important host for the spread of resistance genes. Resistance to antibiotics such as tetracyclines, macrolides, aminoglycosides, β-lactams, sulfonamides, chloramphenicol and quinolones has been reported in S. suis. S. suis has gradually become a reservoir host for antibiotic resistance genes, promoting the accelerated spread of antibiotic resistance genes in bacteria of different species, and has become an important pathogen that seriously threatens public health security.
[0005] Due to the long-term abuse of antibiotics, the resistance of Pleuropneumoniae, Streptococcus suis and Staphylococcus suis to antibiotics has increased. The above bacteria have been found to be resistant to many antibiotics. This leads to the need for treatment with larger doses of antibiotics, greatly increasing the risk of breeding and drug residues and food safety. In addition, excessive abuse of antibiotics can also lead to the emergence of highly resistant bacteria, posing a major threat to animal husbandry and public health. At present, reducing the use of antibiotics and finding alternative strategies for antibiotics have become a broad consensus for the prevention and control of bacterial infections.
[0006] Cinnamaldehyde is a natural small molecule existing in nature, also known as (E)-3-phenyl-2-propenal. The molecular formula of this compound is C 9 H 8O , molecular weight 132.16,, CAS registration number: 14371-10-9, structural formula:
[0007]
[0008] All naturally occurring cinnamaldehydes in nature are trans structures, and trans-cinnamaldehyde has some biological importance. Studies have shown that trans-cinnamaldehyde has certain antibacterial and antioxidant activities. It can interact with bacterial cell membranes and destroy the integrity of cell membranes to exert antibacterial effects. It can also scavenge free radicals and reduce oxidative stress to exert antioxidant effects. Trans-cinnamaldehyde is a synthetic food flavoring allowed for use in GB2760-2014. It can be used to prepare flavors for meat, condiments, oral care products, chewing gum, and candy. Trans-cinnamaldehyde is allowed to be used as a feed additive in the local standard DB37 / T 3614-2019. Therefore, its safety and application in animals are relatively wide.
[0009] Regarding the antibacterial application of trans-cinnamaldehyde, see: CN103391774B: Pharmaceutical composition containing trans-cinnamaldehyde and its use in treating infection, which clearly points out that cinnamon essential oil, especially cinnamon essential oil containing trans-cinnamaldehyde, or trans-cinnamaldehyde itself is a known effective antimicrobial agent.
[0010] Regarding the combined application of trans-cinnamaldehyde and other antibiotics, see: CN113855680B: Application of cinnamaldehyde combined with ceftriaxone sodium, which discloses that when sub-inhibitory concentrations of cinnamaldehyde are used in combination with 512 μg / mL of ceftriaxone sodium, Salmonella basically does not grow within 24 hours, and 1 / 4 MIC concentrations of cinnamaldehyde and 1 / 8 MIC concentrations of ceftriaxone sodium can inhibit the proliferation of Salmonella. Summary of the invention
[0011] The main purpose of the present invention is to provide an antibacterial composition, which has a good inhibitory or killing effect on multidrug-resistant Bacillus pleuropneumoniae, Streptococcus suis, and Staphylococcus suis, can reverse resistant antibiotics into sensitive antibiotics, significantly reduce the use of commonly used antibiotics, improve quality and efficiency, and at the same time avoid antibiotic residues in pork food to ensure food safety.
[0012] At the same time, the invention also provides the application and medicine of the antibacterial combination.
[0013] The technical solution of the present invention is as follows:
[0014] Use of a combination of trans-cinnamaldehyde and an antibiotic in the preparation of a medicament for preventing and treating drug-resistant bacterial infections;
[0015] The antibiotic is one or more combinations of amoxicillin, penicillin G, ciprofloxacin, erythromycin and lincomycin.
[0016] In the above-mentioned use, the ratio of trans-cinnamaldehyde to antibiotic is: 1-1.56 μM: 1.56-400 μg / ml.
[0017] In the above-mentioned use, the drug-resistant bacteria are one or more of Klebsiella Pleuropneumoniae, Streptococcus suis, and Staphylococcus suis.
[0018] Meanwhile, the invention discloses an antibacterial composition, comprising trans-cinnamaldehyde and antibiotics; the antibiotics are one or more combinations of amoxicillin, penicillin G, ciprofloxacin, erythromycin and lincomycin.
[0019] In the above antibacterial composition, the ratio of trans-cinnamaldehyde to antibiotic is: 1-1.56 μM: 1.56-400 μg / ml.
[0020] Finally, the present invention also discloses a medicine containing the antibacterial combination as described above.
[0021] In the above-mentioned medicine, the dosage form of the medicine is oral solution, injection, tablet, granule or microcapsule.
[0022] One of the above technical solutions of the present invention has at least one of the following advantages or beneficial effects:
[0023] The composition of the invention has good inhibitory or killing effects on multi-drug resistant Bacillus pleuropneumoniae, Streptococcus suis and Staphylococcus suis.
[0024] The composition of the present invention can reverse drug-resistant antibiotics into sensitive antibiotics, significantly reduce the use of commonly used antibiotics, improve quality and efficiency, and at the same time avoid antibiotic residues in pork food to ensure food safety. BRIEF DESCRIPTION OF THE DRAWINGS
[0025] The present invention is further described below in conjunction with the accompanying drawings and embodiments;
[0026] Figure 1A The results of the MIC and MBC test of trans-cinnamaldehyde against multi-drug resistant Staphylococcus aureus strain SG-7 are statistically shown;
[0027] Figure 1B The photo shows the results of the determination of MIC and MBC of trans-cinnamaldehyde against multidrug-resistant Staphylococcus aureus strain SG-7;
[0028] Figure 2 There are blank control group, Streptococcus suis infection group, Streptococcus suis infection group and cinnamaldehyde administration group. Photos of mice after infection;
[0029] Figure 3 There are blank control group, Streptococcus suis infection group, Streptococcus suis infection group and cinnamaldehyde administration group. Survival curve of mice after infection. DETAILED DESCRIPTION
[0030] The embodiments of the present invention are described in detail below, and examples of the embodiments are shown in the accompanying drawings, wherein the same or similar reference numerals represent the same or similar elements or elements having the same or similar functions from beginning to end. The embodiments described below with reference to the accompanying drawings are exemplary and are only used to explain the present invention, and cannot be understood as limiting the present invention.
[0031] The Staphylococcus suis SG-7 strain used in the embodiments of the present invention is obtained from the Animal Health Institute of Guangdong Academy of Agricultural Sciences and is a conventional strain well known to those skilled in the art. Staphylococcus suis obtained from other channels is also applicable to the present invention.
[0032] Implementation Case 1
[0033] Ten antimicrobial drugs (Table 1) and trans-cinnamaldehyde were used as test drugs to conduct the following performance verification:
[0034] 1. Bacterial Culture
[0035] Staphylococcus hyosus SG-7 was inoculated into Luria Broth medium (LB medium), shaken at 37°C and 220 rpm overnight, and the bacteria were collected by centrifugation.
[0036] 2. Drug sensitivity test of bacteria to commonly used antibiotics
[0037] Prepare and dilute the stock solution according to the guidelines set by the Clinical and Laboratory Standards Institute (CLSI). Resuspend the bacteria in 3 ml of saline, mix well and compare the turbidity with the bacterial solution in a turbidimetric tube. Use white paper with black text as the background and adjust the turbidity to the same as the turbidimetric tube (0.5 McFarland units). Dip a sterile cotton swab into the adjusted bacterial suspension, squeeze out the excess bacterial suspension on the tube wall, and repeatedly spread it on the LB agar plate three times, rotating the plate 60° each time, and finally spread it around the plate twice to ensure uniform coating. After standing at room temperature for 3-5 minutes, stick the corresponding standard drug sensitivity paper (6 mm in diameter) and incubate the plate at 37°C for 18-24 hours. Measure the diameter of the inhibition zone with a vernier caliper and judge according to the standards of the Clinical Laboratory Standards Institute (CLSI) of the United States. The area without obvious growth visible to the naked eye is the edge of the inhibition zone. The growth of extremely small colonies can be ignored and reported as sensitive [S], intermediate [I], and resistant [R]. The drug sensitivity results are as follows: SG-7 strain is sensitive only to ampicillin / sulbactam, cephalothin and cefazolin, tends to be between sensitive and resistant to ciprofloxacin and vancomycin, and is resistant to the rest of the tested drugs. It can be seen that SG-7 is a highly resistant strain.
[0038] Table 1 Results of drug sensitivity test of Staphylococcus suis SG-7 strain
[0039]
[0040]
[0041] 3. Determination of minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) of trans-cinnamaldehyde against bacteria
[0042] The minimum inhibitory concentration of the drug was determined by the micro-dilution method. The specific operation is as follows:
[0043] Add 190μL of culture medium to the first well of a 96-well plate, and 100μL of culture medium to each of the remaining wells. Add 10μL of 1000mM trans-cinnamaldehyde stock solution to the first well and mix well. Then aspirate 100μL from the first well and add it to the second well and mix well. Aspirate 100μL from the third well and add it to the fourth well and mix well. And so on, until the 10th well. No addition is made to the 11th and 12th wells, as blank controls, take the cultured Staphylococcus suis SG-7 bacterial suspension, the concentration of which is equivalent to the bacterial suspension of 0.5 McFarland turbidity standard, dilute it 1:1000 with culture medium, and add 100μl to each well. Set up 3 replicates for each well, and make a set of controls to avoid drug color interference. Place in a 37℃ normal air incubator and incubate for 16-20 hours to determine the results. The lowest drug concentration well with no colonies and a clear state is the minimum inhibitory concentration (MIC) of Staphylococcus suis SG-7. 600 Read the numbers to assist in judgment. Puff and mix the bacterial solution in the above well plate, aspirate 100ul of the wells with MIC and higher concentration of drug solution, and aspirate each onto the LB agar culture plate. Use a spreader to spread the bacterial solution until the bacterial solution covers the culture plate. Place in a 37℃ ordinary air incubator for overnight culture, and take photos for record. The minimum dilution of the drug with less than 5 colonies on the culture plate is the minimum bactericidal concentration (MBC). The results are as follows Figure 1A and Figure 1B shown.
[0044] The minimum inhibitory concentration (MIC) of trans-cinnamaldehyde against Staphylococcus suis SG-7 was 1.6mM (211.4μg / ml), and the minimum bactericidal concentration (MBC) was 6.3mM (832.6μg / ml). At the concentration of MIC / 2, it still had a certain antibacterial effect.
[0045] In addition, the same determination method was used to determine the MIC and MBC of trans-cinnamaldehyde against Staphylococcus aureus (ATCC 6538), Streptococcus suis, Actinobacillus pleuropneumoniae, and Haemophilus parasuis. The results are shown in Table 2.
[0046] Table 2 Minimum inhibitory concentration (MIC) of trans-cinnamaldehyde combined with antibacterial drugs against SG-7 resistant bacteria
[0047]
[0048] The results showed that trans-cinnamaldehyde had good antibacterial and bacteriostatic effects on Staphylococcus aureus (ATCC 6538), Streptococcus suis, and Actinobacillus pleuropneumoniae, but had no significant effect on Haemophilus parasuis.
[0049] Implementation Case 2
[0050] Trans-cinnamaldehyde was combined with different antibacterial drugs for antibacterial performance verification against Staphylococcus suis:
[0051] Determination of minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) of trans-cinnamaldehyde combined with antibacterial drugs against SG-7 resistant bacteria
[0052] Trans-cinnamaldehyde-containing culture medium was prepared in advance, with concentrations of 1000 μM, 400 μM, 200 μM, 100 μM, 10 μM, and 1 μM, respectively, and no trans-cinnamaldehyde was added as a blank control. For each concentration, 190 μL of culture medium containing trans-cinnamaldehyde was added to the first well of different rows of a 96-well plate, and 100 μL of culture medium was added to each of the remaining wells. Amoxicillin was diluted using the micro-two-fold dilution method in step 2 of implementation case 1, with the highest concentration being 50 μg / ml amoxicillin. The remaining operating steps were the same, and the inhibitory effects of different concentrations of trans-cinnamaldehyde and different antimicrobial drug combinations on multidrug-resistant porcine Staphylococcus aureus strain SG-7 were determined. The results are shown in Tables 3 and 4. At a concentration of 1000 μM, the MIC concentration of amoxicillin against SG-7 resistant strains was reduced by 32 times, and the MBC concentration was reduced by 4 times.
[0053] According to the method of step 1 of implementation case 1, the inhibitory effects of antimicrobial drugs: penicillin G, ciprofloxacin, erythromycin, and lincomycin, respectively combined with trans-cinnamaldehyde, on multi-drug resistant Staphylococcus suis strain SG-7 were also determined. The results are shown in Tables 2 and 3.
[0054] Table 3 Minimum inhibitory concentration (MIC) of trans-cinnamaldehyde combined with antibacterial drugs against SG-7 resistant bacteria
[0055]
[0056]
[0057] Table 4 Minimum bactericidal concentration (MBC) of trans-cinnamaldehyde combined with various antimicrobial drugs against SG-7 resistant bacteria
[0058]
[0059] In Tables 3 and 4, the dosage unit of each antibiotic is μg / ml;
[0060] The results show that:
[0061] 1. Trans-cinnamaldehyde can reduce the MIC and MBC values of various types of antimicrobial drugs, increase the sensitivity of SG-7 resistant strains to various types of antimicrobial drugs, and significantly reduce the use of antibiotics.
[0062] 2. As can be seen from Table 3, when 1 / 4MIC trans-cinnamaldehyde is used, 1 / 16MIC amoxicillin, 1 / 8MIC penicillin G, 1 / 8MIC ciprofloxacin, 1 / 32MIC erythromycin, and 1 / 16MIC lincomycin are required;
[0063] When the dosage of 1 / 8MIC trans-cinnamaldehyde is used, 1 / 8MIC amoxicillin, 1 / 4MIC penicillin G, 1 / 4MIC ciprofloxacin, 1 / 8MIC erythromycin, and 1 / 4MIC lincomycin are required;
[0064] When the dosage of 1 / 16MIC trans-cinnamaldehyde is used, 1 / 4MIC amoxicillin, 1 / 4MIC penicillin G, 1 / 4MIC ciprofloxacin, 1 / 4MIC erythromycin, and 1 / 2MIC lincomycin are required;
[0065] This indicates that trans-cinnamaldehyde and many antibiotics can produce synergy in inhibiting SG-7 resistant bacteria, especially at 1 / 4MIC trans-cinnamaldehyde dosage and 5 / 8MIC, which can significantly reduce the dosage of antibiotics, with the reduction being up to 64 times.
[0066] 3. As can be seen from Table 4, when the dosage of 4 / 63MBC trans-cinnamaldehyde is used, 1 / 2MBC amoxicillin, 1 / 8MBC penicillin G, 1 / 2MBC ciprofloxacin, <1 / 4MBC erythromycin, and <1 / 2MBC lincomycin are required;
[0067] When using 2 / 63MBC trans-cinnamaldehyde, you need 1MBC amoxicillin, 1 / 4MBC penicillin G, 1 / 2MBC ciprofloxacin, and 1 / 2MBC erythromycin;
[0068] When using 1 / 64MBC trans-cinnamaldehyde, you need 1MBC amoxicillin, 1 / 2MBC penicillin G, and 1 / 2MBC ciprofloxacin.
[0069] This indicates that trans-cinnamaldehyde and many antibiotics can produce synergy in killing SG-7 resistant bacteria, especially at 1 / 4MIC trans-cinnamaldehyde dosage and 5 / 8MIC, which can significantly reduce the dosage of antibiotics, with the reduction range being up to 16 times.
[0070] Implementation Case 3
[0071] A mouse meningitis model was constructed to evaluate the effect of cinnamaldehyde in resisting Streptococcus suis infection in vivo.
[0072] The preparation of Streptococcus suis liquid and infection of mice were carried out as follows: the challenge bacteria were revived by three lines on the TSA plate, inverted in a 37°C incubator, and cultured for 18 hours. A single colony was picked from the TSA plate with a sterilized white gun tip using tweezers and placed in 5 mL of TSB broth containing 5% bovine serum, and placed in a shaker (37°C, 170 rpm) for proliferation for 18 hours. The liquid in the test tube changed from clear to turbid, and fresh bacterial liquid was obtained. The fresh bacterial liquid was diluted 10 times with TSB broth containing 5% serum to a suitable gradient, 100 μL of the diluted bacterial liquid was drawn onto the common lower plate (do three replicates), and evenly spread with a sterile spreader stick. After the surface of the plate was dry, it was inverted in a 37°C incubator and cultured for 18 hours. The number of colonies on the plate was counted, and the concentration of the bacterial liquid was calculated [calculation formula: bacterial liquid concentration (CFU / mL) = average colony number × dilution factor × 10]. The bacterial solution was diluted to 1x10^9 / ml with PBS and injected intramuscularly into mice. Each mouse in the infection group was injected intramuscularly with 100 μL S. suis 2 bacterial solution, and the blank control group was injected with an equal volume of PBS.
[0073] Cinnamaldehyde was injected at a dosage of 24 mg / kg / mouse, with an average weight of 25 g / mouse. 20 mg of cinnamaldehyde was dissolved in 16.7 ml of PBS to a concentration of 1.2 mg / ml cinnamaldehyde. Each mouse was intraperitoneally injected with 0.5 ml of 1.2 mg / ml cinnamaldehyde.
[0074] The animals were divided into blank control group, Streptococcus suis infection group, and Streptococcus suis infection group and cinnamaldehyde administration group. The mice were observed for three days after infection, and the status of the mice was recorded and the survival curve of the mice was calculated. Figure 2 and Figure 3 shown.
[0075] The results showed that cinnamaldehyde could reduce brain tissue congestion in mice and significantly reduce the mortality rate of mice infected with Streptococcus suis.
Claims
1. Use of a combination of trans-cinnamaldehyde and an antibiotic in the preparation of a drug for preventing and treating drug-resistant bacterial infections; The antibiotic is one or more combinations of amoxicillin, penicillin G, ciprofloxacin, erythromycin and lincomycin.
2. The use according to claim 1, characterized in that The ratio of trans-cinnamaldehyde to antibiotic is: 1-1.56 μM: 1.56-400 μg / ml.
3. The use according to claim 1, characterized in that The drug-resistant bacteria are one or more of Bacillus pleuropneumoniae, Streptococcus suis, and Staphylococcus suis.
4. An antibacterial composition, characterized in that The invention comprises trans-cinnamaldehyde and antibiotics; the antibiotics are one or more combinations of amoxicillin, penicillin G, ciprofloxacin, erythromycin and lincomycin.
5. The antibacterial composition according to claim 4, characterized in that The ratio of trans-cinnamaldehyde to antibiotic is: 1-1.56 μM: 1.56-400 μg / ml.
6. A drug, characterized in that Contains the antibacterial combination as claimed in claim 4 or 5.
7. The drug according to claim 6, characterized in that The dosage form of the drug is oral solution, injection, tablet, granule or microcapsule.
